EB 8018Alternative Names: EB8018
Latest Information Update: 28 Dec 2016
At a glance
- Originator Vertex Pharmaceuticals
- Developer Enterome
- Mechanism of Action Adhesion receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Crohn's disease